175 related articles for article (PubMed ID: 25287561)
1. Prognostic significance of steroid receptor positivity and adjuvant progestogen use in endometrial stromal sarcoma.
Cade TJ; Quinn MA; Rome RM; Polyakov A
Aust N Z J Obstet Gynaecol; 2014 Oct; 54(5):453-6. PubMed ID: 25287561
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between receptor status and results of treatment in endometrial carcinoma].
Baĭnazarova AA; Iskakova ZhK
Vopr Onkol; 2006; 52(6):654-8. PubMed ID: 17338243
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
4. Endometrial stromal sarcoma involving the urinary bladder: a study of 6 cases.
Tian W; Latour M; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):982-9. PubMed ID: 24705317
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases.
Yoon A; Park JY; Park JY; Lee YY; Kim TJ; Choi CH; Bae DS; Kim BG; Lee JW; Nam JH
Gynecol Oncol; 2014 Jan; 132(1):70-5. PubMed ID: 24184602
[TBL] [Abstract][Full Text] [Related]
6. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.
Bodner K; Bodner-Adler B; Obermair A; Windbichler G; Petru E; Mayerhofer S; Czerwenka K; Leodolter S; Kainz C; Mayerhofer K
Gynecol Oncol; 2001 May; 81(2):160-5. PubMed ID: 11330943
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
8. Low-grade endometrial stromal sarcoma: hormonal aspects.
Chu MC; Mor G; Lim C; Zheng W; Parkash V; Schwartz PE
Gynecol Oncol; 2003 Jul; 90(1):170-6. PubMed ID: 12821359
[TBL] [Abstract][Full Text] [Related]
9. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas.
Reich O; Regauer S; Urdl W; Lahousen M; Winter R
Br J Cancer; 2000 Mar; 82(5):1030-4. PubMed ID: 10737385
[TBL] [Abstract][Full Text] [Related]
10. Ovarian preservation in stage I low-grade endometrial stromal sarcomas.
Li AJ; Giuntoli RL; Drake R; Byun SY; Rojas F; Barbuto D; Klipfel N; Edmonds P; Miller DS; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1304-8. PubMed ID: 16319256
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.
Dahhan T; Fons G; Buist MR; Ten Kate FJ; van der Velden J
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):80-4. PubMed ID: 19269732
[TBL] [Abstract][Full Text] [Related]
12. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
14. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases.
Bai H; Yang J; Cao D; Huang H; Xiang Y; Wu M; Cui Q; Chen J; Lang J; Shen K
Gynecol Oncol; 2014 Mar; 132(3):654-60. PubMed ID: 24412112
[TBL] [Abstract][Full Text] [Related]
15. Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: A multicenter review.
Stewart LE; Beck TL; Giannakopoulos NV; Rendi MH; Isacson C; Goff BA
Gynecol Oncol; 2018 May; 149(2):297-300. PubMed ID: 29534832
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.
Serkies K; Abacjew-Chmyłko A; Wieczorek-Rutkowska M; Pęksa R
Ginekol Pol; 2018; 89(11):607-610. PubMed ID: 30508212
[TBL] [Abstract][Full Text] [Related]
17. Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study.
Seagle BL; Shilpi A; Buchanan S; Goodman C; Shahabi S
Gynecol Oncol; 2017 Aug; 146(2):254-262. PubMed ID: 28596015
[TBL] [Abstract][Full Text] [Related]
18. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study.
Schick U; Bolukbasi Y; Thariat J; Abdah-Bortnyak R; Kuten A; Igdem S; Caglar H; Ozsaran Z; Lössl K; Schleicher U; Zwahlen D; Villette S; Vees H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e757-63. PubMed ID: 22300565
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
20. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.
Park JY; Baek MH; Park Y; Kim YT; Nam JH
Virchows Arch; 2018 Jul; 473(1):61-69. PubMed ID: 29869299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
